Kaleido Biosciences, Inc. (KLDO)
| Market Cap | 94.99M |
| Revenue (ttm) | 855,000 |
| Net Income (ttm) | -90.03M |
| Shares Out | 42.59M |
| EPS (ttm) | -2.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,230 |
| Open | 2.10 |
| Previous Close | 2.10 |
| Day's Range | 2.06 - 2.32 |
| 52-Week Range | 1.90 - 20.50 |
| Beta | -0.39 |
| Analysts | Buy |
| Price Target | 14.80 (+563.7%) |
| Earnings Date | n/a |
About KLDO
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. It a...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for KLDO stock is "Buy." The 12-month stock price forecast is 14.80, which is an increase of 563.68% from the latest price.
News
Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress
LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory con...
Kaleido Biosciences, Inc. (KLDO) Sees Hammer Chart Pattern: Time to Buy?
Kaleido Biosciences, Inc. (KLDO) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Th...
LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory con...
Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory con...
Here's Why Kaleido Biosciences, Inc. (KLDO) Is a Great 'Buy the Bottom' Stock Now
Kaleido Biosciences, Inc. (KLDO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...
Kaleido Biosciences, Inc. (KLDO) Reports Q3 Loss, Misses Revenue Estimates
Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 1.82% and -58.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...
Kaleido Biosciences Reports Third Quarter 2021 Financial Results
--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease...
Down 23.6% in 4 Weeks, Here's Why Kaleido Biosciences, Inc. (KLDO) Looks Ripe for a Turnaround
Kaleido Biosciences, Inc. (KLDO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn...
Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory con...
Why Did Kaleido Shares Plunge 10% On Tuesday?
Kaleido Biosciences Inc (NASDAQ: KLDO) announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT), in mild-to-moderate ulcerative colitis (UC...
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informatio...
Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, ...
Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented
FDA Questions Kaleido Biosciences 'Non-IND' COVID-19 Trial
The FDA has issued a warning letter to Kaleido Biosciences Inc (NASDAQ: KLDO), blasting its “failure to submit Investigational New Drug applications for a clinical trial with an investigational new drug...
Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference
LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micro...
Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates
Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 5.08% and -15.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Kaleido Biosciences Reports Second Quarter 2021 Financial Results
--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the de...
Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical...
On track to initiate Phase 2 trial in the first quarter of 2022 On track to initiate Phase 2 trial in the first quarter of 2022
Kaleido Biosciences Announces New Chairperson Appointment to its Board of Directors
Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors
Kaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference
LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
Kaleido Biosciences Reports First Quarter 2021 Financial Results
--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109's potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-...
Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic ...
LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to tr...
Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit
LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbi...